CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D001342: Autonomic Nervous System Diseases NIH

(Synonyms: Autonomic Nervous System Diseases)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug1158 Reverse-transcription polymerase chain reaction (RT-PCR) Wiki 1.00
drug450 ECG-Holter Wiki 1.00
drug305 Chest computed tomography (CT) Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D054969 Primary Dysautonomias NIH 1.00

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Testing for Dysautonomia in Patients Hospitalized for SARS-CoV-2 Infection (COVID-19) : COVIDANS Study

A number of clinical features suggest the possibility of dysautonomia in patients infected with SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). At the same time, there is now strong experimental evidence that SARS-CoV-2 can cross the blood-brain barrier, probably via the olfactory nerves, and reach the brain stem, which is located in close proximity. Damage to the brainstem nuclei could explain the suspected dysautonomic episodes, but also the severity of respiratory distress in infected patients, and the difficulty of ventilatory withdrawal encountered in resuscitation, potentially through damage to the ventilation control and regulation centers located in the brainstem. The objective of this study is to record the long term variability in heart rate, reflecting autonomic balance, of patients screened positive for SARS-CoV-2 throughout their stay in conventional care units at the Saint-Etienne University Hospital, in order to see whether there is an autonomic imbalance at screening, whether the worsening of the autonomic imbalance precedes the worsening of the clinical condition, and how quickly the expected correction of the autonomic imbalance follows or precedes that of the disease.

NCT04374045 SARS-CoV 2 Other: ECG-Holter
MeSH:Primary Dysautonomias Autonomic Nervous System Diseases

Primary Outcomes

Description: Dysautonomia will be measured by the LF/HF ratio (sympatho-vagal balance), obtained from a Holter-ECG recording over the first 24 hours of hospitalisation, and compared to normal values given by charts for each age group and sex, making it possible to obtain the percentage of dysautonomic patients.

Measure: Percentage of dysautonomia patients found within the first 24 hours of hospitalization (%)

Time: Hours: 24

Secondary Outcomes

Description: Measured by the LF/HF ratio (sympathy-vagal balance)

Measure: Analyse the other mathematical indices measuring autonomic balance, obtained by Holter-ECG recording over the first 24 hours and throughout their hospitalisation, in search of possible dysautonomia

Time: up to 5 months

Description: Measured by the LF/HF ratio (sympathy-vagal balance)

Measure: To investigate whether the autonomic balance of patients with CoV-2 SARS correlates with the severity of their clinical condition during their hospital stay.

Time: up to 5 months

Description: Measured by the LF/HF ratio (sympathy-vagal balance)

Measure: To investigate whether the various autonomic parameters recorded are predictive of clinical worsening or improvement, by calculating a prediction threshold for each of the parameters.

Time: up to 5 months


HPO Nodes